论文部分内容阅读
目的观察消瘿合剂联合糖皮质激素治疗活动期Ⅲ级以上甲状腺相关性眼病(TAO)的临床疗效。方法将60例活动期Ⅲ级以上甲状腺相关性眼病患者随机分为治疗组与对照组,每组30例。两组均予甲强龙激素冲击疗法,同时治疗组予消瘿合剂口服,对照组予消瘿合剂安慰剂口服。两组疗程均为3个月,观察临床疗效,比较甲状腺相关性眼病病情分级(NOSPECS)、疾病活动度评分(CAS)的变化情况。结果 (1)治疗组、对照组临床总有效率分别为93.33%和83.33%;组间临床疗效比较,治疗组明显优于对照组(P<0.05)。(2)组间治疗后NOSPECS病情分级比较,治疗组较对照组改善更加明显(P<0.05)。(3)治疗前后组内比较,两组CAS临床活动度评分差异均有统计学意义(P<0.05);组间治疗前后CAS临床活动度评分差值比较,治疗组明显高于对照组(P<0.05)。结论与单纯激素冲击疗法相比,联用消瘿合剂能更加明显地缓解活动期Ⅲ级以上TAO患者的临床症状,控制病情进展。
Objective To observe the clinical efficacy of Xiaoyao Mixture combined with glucocorticoid therapy for stage Ⅲ thyroid associated ophthalmopathy (TAO). Methods Sixty patients with stage III or higher thyroid associated ophthalmopathy were randomly divided into treatment group and control group, with 30 cases in each group. Both groups were given methylprednisolone impact therapy, while the treatment group was given Xiaoyan mixture oral, the control group Xiaoxiao Mixture placebo oral. The two groups were treated for 3 months to observe the clinical curative effect, compare the changes of NOSPECS and CAS. Results (1) The total clinical effective rates of the treatment group and the control group were 93.33% and 83.33%, respectively. The clinical efficacy of the treatment group was significantly better than that of the control group (P <0.05). (2) Compared with the grading of NOSPECS in the treatment group, the treatment group improved more obviously than the control group (P <0.05). (3) There was significant difference in CAS clinical activity scores between the two groups before and after treatment (P <0.05). Differences in CAS clinical activity scores between the two groups before and after treatment were significantly higher in the treatment group than in the control group (P <0.05). Conclusions Compared with the simple hormone therapy, the combination of Xiaoyan mixture can obviously relieve the clinical symptoms and control the progression of the disease in patients with stage Ⅲ or higher TAO.